Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia
Biohaven (NYSE: BHVN) has announced a conference call and webcast scheduled for Monday, September 23, 2024, at 8:30 a.m. Eastern Time. The purpose of this event is to discuss topline data from Study BHV4157-206-RWE (NCT06529146), which was designed in collaboration with the US Food and Drug Administration (FDA) to evaluate the effectiveness of troriluzole in Spinocerebellar Ataxia.
Interested parties can access the live event through the Investor Relations section of Biohaven's website. For those wishing to participate via telephone, registration is required, after which a dial-in number and unique PIN will be provided for conference call access.
Biohaven (NYSE: BHVN) ha annunciato una conferenza telefonica e un webcast programmati per lunedì 23 settembre 2024, alle 8:30 ora orientale. Lo scopo di questo evento è discutere i dati preliminari dello Studio BHV4157-206-RWE (NCT06529146), progettato in collaborazione con la Food and Drug Administration (FDA) degli Stati Uniti per valutare l'efficacia del troriluzolo nell'Atassia Spinocerebellare.
Le parti interessate possono accedere all'evento in diretta attraverso la sezione Relazioni con gli Investitori del sito web di Biohaven. Per coloro che desiderano partecipare telefonicamente, è necessaria la registrazione, dopo la quale verrà fornito un numero di accesso e un PIN unico per la conferenza.
Biohaven (NYSE: BHVN) ha anunciado una llamada de conferencia y un webcast programados para el lunes 23 de septiembre de 2024 a las 8:30 a.m. hora del Este. El propósito de este evento es discutir los datos preliminares del Estudio BHV4157-206-RWE (NCT06529146), diseñado en colaboración con la Administración de Alimentos y Medicamentos de EE. UU. (FDA) para evaluar la efectividad del troriluzol en la Ataxia Espinocerebelosa.
Las partes interesadas pueden acceder al evento en vivo a través de la sección de Relaciones con Inversores del sitio web de Biohaven. Para aquellos que deseen participar por teléfono, se requiere registro, tras el cual se proporcionará un número de acceso y un PIN único para la llamada de conferencia.
Biohaven (NYSE: BHVN)는 2024년 9월 23일 월요일 오전 8시 30분 동부 표준시로 예정된 컨퍼런스 콜과 웹캐스트를 발표했습니다. 이 이벤트의 목적은 Study BHV4157-206-RWE (NCT06529146)의 주요 데이터에 대해 논의하는 것입니다. 이 연구는 미국 식품의약국(FDA)와 협력하여 Spinocerebellar Ataxia에서의 트로릴루졸 효과를 평가하기 위해 설계되었습니다.
관심 있는 분들은 Biohaven 웹사이트의 투자자 관계 섹션을 통해 라이브 이벤트에 접근할 수 있습니다. 전화로 참여하고자 하는 분들은 등록이 필요하며, 등록 후 컨퍼런스 콜 접속을 위한 다이얼 인 번호와 고유 PIN이 제공됩니다.
Biohaven (NYSE: BHVN) a annoncé une conférence téléphonique et un webcast prévus pour le lundi 23 septembre 2024 à 8h30, heure de l'Est. Le but de cet événement est de discuter des données préliminaires de l'étude BHV4157-206-RWE (NCT06529146), conçue en collaboration avec la Food and Drug Administration (FDA) des États-Unis pour évaluer l'efficacité du troriluzole dans l'ataxie spinocérébelleuse.
Les parties intéressées peuvent accéder à l'événement en direct via la section Relations avec les Investisseurs du site web de Biohaven. Pour ceux qui souhaitent participer par téléphone, une inscription est requise, après quoi un numéro de composition et un code PIN unique seront fournis pour l'accès à la conférence.
Biohaven (NYSE: BHVN) hat eine Telefonkonferenz und einen Webcast angekündigt, die für Montag, den 23. September 2024, um 8:30 Uhr Eastern Time geplant sind. Zweck dieser Veranstaltung ist es, die Primärdaten aus der Studie BHV4157-206-RWE (NCT06529146) zu diskutieren, die in Zusammenarbeit mit der US-amerikanischen Food and Drug Administration (FDA) entworfen wurde, um die Wirksamkeit von Troriluzol bei der Spinocerebellären Ataxie zu bewerten.
Interessierte Parteien können auf die Live-Veranstaltung über den Bereich Investor Relations auf der Website von Biohaven zugreifen. Für diejenigen, die telefonisch teilnehmen möchten, ist eine Anmeldung erforderlich, nach der eine Einwahlnummer und eine einzigartige PIN für den Zugang zur Telefonkonferenz bereitgestellt werden.
- None.
- None.
- Conference call and webcast to be held Monday, September 23, at 8:30am ET
Conference Call and Webcast Details
Biohaven will hold a live conference call and webcast Monday, September 23, 2024, at 8:30 a.m. Eastern Time. The live event may be accessed via the Investor Relations portion of Biohaven's website at https://ir.biohaven.com/events-presentations/events. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call.
About Troriluzole
Troriluzole is a new chemical entity (NCE) and third-generation prodrug that modulates glutamate, the most abundant excitatory neurotransmitter in the human body. The primary mode of action of troriluzole is reducing synaptic levels of glutamate. Troriluzole increases glutamate uptake from the synapse, by augmenting the expression and function of excitatory amino acid transporters located on glial cells that play a key role in clearing glutamate from the synapse. Troriluzole has the potential to be developed in a number of other diseases associated with excessive glutamate. More information about troriluzole can be found at the Biohaven's website: https://www.biohaven.com/pipeline/clinical-programs/glutamate/.
About Biohaven
Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. The company is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for OCD and SCA (spinocerebellar ataxia); myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity; antibody recruiting bispecific molecules and antibody drug conjugates for cancer. For more information, visit www.biohaven.com.
Forward-looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable U.S. regulatory requirements; the potential commercialization of Biohaven's product candidates; the potential for Biohaven's product candidates to be first in class therapies; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
+1 (312) 961-2502
View original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-announces-conference-call-to-discuss-topline-pivotal-study-results-in-spinocerebellar-ataxia-302254638.html
SOURCE Biohaven Ltd.
FAQ
When is Biohaven (BHVN) hosting a conference call to discuss troriluzole study results?
What is the purpose of Biohaven's (BHVN) upcoming conference call?
How can investors access Biohaven's (BHVN) conference call on September 23, 2024?
What is the clinical trial number for Biohaven's (BHVN) Spinocerebellar Ataxia study?
